2024-10-07 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis:

**1. Performance Comparison:**

Regeneron Pharmaceuticals Inc. (REGN) has delivered a cumulative return of 92.97%, lagging behind the S&P 500 (VOO) which has gained 133.14%. The current performance gap stands at -40.17%, indicating that REGN is currently underperforming the S&P 500. This gap represents 35.43% of the historical maximum spread between the two returns.

**2. Recent Price Movement:**

* **Closing Price:** $1012.82
* **5-Day Moving Average:** $1033.17
* **20-Day Moving Average:** $1094.86
* **60-Day Moving Average:** $1115.43

The current closing price is below all moving averages, indicating a potential short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 22.12 - Suggests the stock is oversold.
* **PPO:** -0.9 - Points to a potential bearish momentum.
* **Delta_Previous_Relative_Divergence:** -27.97 - Signals a recent short-term decline in relative performance.
* **Expected Return:** 0.0% - This represents the potential 5-year expected return (over S&P 500) based on current investment levels.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

The latest earnings report (2024-08-01) shows EPS of 13.25, exceeding analysts' expectations. Revenue also came in higher at 3.55 billion dollars. This strong performance indicates positive growth momentum for Regeneron.

**5. News and Recent Issues:**

Recent market outlook for Regeneron is positive, with analysts expecting continued growth driven by its strong pipeline and innovative products. Notably, the success of its eye drug, Eylea, continues to drive revenue, and its new drug for high cholesterol,  **"**[Drug name]**,** is expected to perform well in the market.

**6. Overall Analysis:**

While REGN is currently underperforming the S&P 500, its recent earnings report suggests strong growth potential. Despite the stock being oversold and experiencing a recent short-term decline, the company's pipeline and new drug launches offer promising future prospects. 

**7. Report in English:**

Regeneron Pharmaceuticals Inc. (REGN) is a leading biotechnology company focused on the discovery, development, and commercialization of life-transforming medicines. Despite its current underperformance against the S&P 500, the company's recent strong earnings report indicates a positive growth trajectory. While technical indicators point to a short-term downturn, the strong performance of its flagship drug, Eylea, and the potential of its new cholesterol medication provide promising future prospects. 

**Overall, while REGN is currently in a downward trend, its strong fundamentals and future potential make it a stock worth considering for long-term investors. However, further analysis and monitoring of market trends and industry dynamics are recommended before making any investment decisions.**

*This analysis is based on the information provided and should not be considered as financial advice. It is important to conduct thorough research and consult with a financial advisor before making any investment decisions.* 
